This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: Cholesterol

March 2008 Br J Cardiol 2008;15:79–81

Familial hypercholesterolaemia: recognising the unrecognised

Jonathan Morrell

Abstract

(more…)

| Full text

March 2008 Br J Cardiol 2008;15:95-100

A UK survey of rosuvastatin in general practice: reaching cholesterol targets

George Kassianos, John Reckless, Cathy Emmas, Marc Evans, Andrea Tree, Andrew Vance

Abstract

Introduction Coronary heart disease (CHD) is responsible for over 100,000 deaths annually in the UK.1 Epidemiology studies have long supported that cholesterol is a key risk factor for cardiovascular disease (CVD).2 In both primary and secondary prevention, statin therapy trials have shown that there is a clear relationship between lowering cholesterol and reducing cardiovascular risk in both primary and secondary prevention.3 However, The World Health Report 2002 estimates that over 50% of CHD globally is still due to elevated blood cholesterol levels.4 Table 1. Recommended targets for total cholesterol (TC) and low-density lipoprotein chol

| Full text

January 2008 Br J Cardiol 2008;15:7-11

New cholesterol-lowering product

BJCardio editorial team

Abstract

The product is a polymer in tablet form that lowers LDL-cholesterol.  It can be taken as adjunctive therapy to diet, in combination with other cholesterol-lowering medications, such as statins, or alone, when statins are inappropriate or not well-tolerated. When combined with statins, colesevelam hydrochloride has been shown to have an additive LDL-cholesterol lowering effect in the range of 8–16%.

| Full text

November 2007 Br J Cardiol 2007;14:280-5

Switching statins: the impact on patient outcomes

Berkeley Phillips, Fayaz Aziz, Christopher P O"Regan, Craig Roberts, Amy E Rudolph, Steve Morant

Abstract

A total of 2,511 switch patients and 9,009 controls were identified. The risk of death or first major cardiovascular event was significantly associated with switching therapy (hazard ratio = 1.30, 95% confidence interval: 1.02–1.64) compared with patients who did not switch. Major cardiovascular events and stroke were also significantly associated with switching. There was no significant difference in all-cause mortality.  While recognising the observational nature of database research, this study has highlighted the potential for poorer cardiovascular outcomes in patients switching statin therapy, compared with patients maintained on thei

| Full text

May 2006 Br J Cardiol 2006;13:191-4

Familial hypercholesterolaemia in children

D Paul Nicholls

Abstract

No content available

| Full text

March 2006 Br J Cardiol 2006;13:145-52

The ‘rule of halves’ still applies to the management of cholesterol in cardiovascular disease: 2002–2005

Simon de Lusignan, Nigel Hague, Jonathan Belsey, Neil Dhoul, Jeremy van Vlymen

Abstract

No content available

| Full text

September 2005 Br J Cardiol 2005;12:397-400

Statin prescribing: is the reality meeting the expectations of primary care?

Adrian JB Brady, John Norrie, Ian Ford

Abstract

No content available

| Full text

September 2005 Br J Cardiol 2005;12:379-86

New approaches to the management of dyslipidaemia

Lena M Izzat, Philip Avery

Abstract

No content available

| Full text

November 2004 Br J Cardiol 2004;11:487-91

Statins in primary care: bridging the treatment gap

Rubin Minhas

Abstract

No content available

| Full text

November 2004 Br J Cardiol 2004;11:449-54

Statin safety in perspective – maximising the risk:benefit

Marc Evans

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now